Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
18.06. | C4 Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
07.05. | C4 Therapeutics halts BRAF degrader work to save cash for cemsidomide | 5 | FierceBiotech | ||
C4 THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
07.05. | C4 Therapeutics, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
07.05. | C4 Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
07.05. | C4 Therapeutics, Inc.: C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights | 225 | GlobeNewswire (Europe) | Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100... ► Artikel lesen | |
14.04. | C4 Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
27.02. | C4 Therapeutics GAAP EPS of -$0.49 beats by $0.02, revenue of $5.2M beats by $0.77M | 4 | Seeking Alpha | ||
27.02. | C4 Therapeutics, Inc.: C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights | 328 | GlobeNewswire (Europe) | Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin's Lymphoma; Trials Expected to Initiate in Early 2026 CFT1946 Phase 1/2 Trial... ► Artikel lesen | |
27.02. | C4 Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
27.02. | C4 Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
27.02. | C4 Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
14.01. | C4 Therapeutics gains after portfolio updates | 2 | Seeking Alpha | ||
14.01. | C4 Therapeutics macht Fortschritte bei wichtigen klinischen Studien für 2025 | 4 | Investing.com Deutsch | ||
14.01. | C4 Therapeutics, Inc.: C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology | 197 | GlobeNewswire (Europe) | Cemsidomide Data Presented at American Society of Hematology (ASH) Annual Meeting Support Best-in-Class Profile; Program Advancing to Next Phase of Clinical Development in Multiple Myeloma and Non-Hodgkin's... ► Artikel lesen | |
14.01. | C4 Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
08.12.24 | C4 Therapeutics, Inc.: C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader | 187 | GlobeNewswire (Europe) | In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR)... ► Artikel lesen | |
28.10.24 | C4 Therapeutics, Inc.: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 179 | GlobeNewswire (Europe) | WATERTOWN, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science... ► Artikel lesen | |
15.10.24 | C4 Therapeutics, Inc.: C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D. | 212 | GlobeNewswire (Europe) | Mahaney Brings More Than 25 Years of Pharmaceutical and Biotech Experience Overseeing Drug Discovery and Expansion of Leading Discovery and Clinical Portfolios Fisher Will Serve as Senior Scientific... ► Artikel lesen | |
30.09.24 | C4 Therapeutics, Inc.: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 78 | GlobeNewswire (Europe) | WATERTOWN, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science... ► Artikel lesen | |
10.09.24 | C4 Therapeutics, Inc.: C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen | 569 | GlobeNewswire (Europe) | Milestone Results in $8 Million Payment to C4 Therapeutics WATERTOWN, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
OCUGEN | 0,770 | -1,33 % | Ocugen erhält zusätzliche 180-Tage-Verlängerung von der Nasdaq | ||
CELLDEX THERAPEUTICS | 19,000 | +1,06 % | Celldex Therapeutics, Inc.: Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025 | Seven months after the completion of dosing: 41% of patients (150 mg Q4W) continue to experience complete response (UAS7=0)48% of patients (150 mg Q4W) report that CSU no longer impacts their quality... ► Artikel lesen | |
COHERUS ONCOLOGY | 0,657 | -2,17 % | Coherus Oncology, Inc.: Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics | REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc.... ► Artikel lesen | |
NEOVACS | 0,002 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 03.06.2025 | Das Instrument TGNA FR0005175080 TRANSGENE SA EO 0,50 EQUITY wird cum Kapitalmassnahme gehandelt am 03.06.2025 und ex Kapitalmassnahme am 04.06.2025 The instrument TGNA FR0005175080 TRANSGENE SA EO... ► Artikel lesen | |
BIOMEA FUSION | 1,670 | 0,00 % | Biomea Fusion, Inc.: Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights | Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway Icovamenib progressing toward the next phase of clinical development in insulin deficient type 2 diabetes patients... ► Artikel lesen | |
SAGIMET BIOSCIENCES | 6,750 | -2,17 % | Sagimet Biosciences Inc.: Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis | Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was well tolerated Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to... ► Artikel lesen | |
CUE BIOPHARMA | 0,616 | +4,23 % | Cue Biopharma, Inc.: Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies | ORR of 50% in treatment-naïve patients with HPV+ R/M HNSCC12-month landmark survival of 88% and mOS of 32 months BOSTON, July 01, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage... ► Artikel lesen | |
SOLID BIOSCIENCES | 4,870 | 0,00 % | Solid Biosciences Inc.: Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CHARLESTOWN, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac... ► Artikel lesen | |
ZURA BIO | 0,940 | +6,21 % | Zura Bio appoints Eric Hyllengren as CFO | ||
NUVALENT | 80,50 | 0,00 % | Goldman Sachs nimmt Nuvalent-Aktie mit Kaufempfehlung in die Bewertung auf | ||
RECURSION PHARMACEUTICALS | 5,210 | 0,00 % | Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process? | ||
CG ONCOLOGY | 26,680 | +1,25 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
BEAM THERAPEUTICS | 19,890 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung für Beam Therapeutics mit Kursziel von 80 US-Dollar | ||
ENLIVEN THERAPEUTICS | 20,640 | +5,04 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress | Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent... ► Artikel lesen | |
TREVI THERAPEUTICS | 5,980 | 0,00 % | Cantor Fitzgerald initiates coverage on Trevi Therapeutics stock with Overweight rating |